Aurealis Therapeutics, a synthetic biology company developing multi-targeting, scalable, low cost of goods cell and gene therapies for high unmet medical needs, announced today that Chief Operating Officer Laurent Décory will attend Swiss Biotech Day 2025, taking place in Basel, Switzerland, from 5-6 May.
As part of the conference, Laurent Décory will also participate in the Microbiome Innovators session, where he will present the company’s 4-in-1 multi-targeting technology. His pitch is scheduled for Monday, May 5 at 16:15 in Room RIO.
The Microbiome Innovators session aims to elevate awareness of microbiome innovation in pharma and offers a unique platform for engaging with experts, investors, and global industry leaders.
“We are proud to present our multi-targeting therapies developed from engineered bacteria to address broad unmet medical needs in chronic wounds, cancer, and inflammatory diseases,” said COO Laurent Décory. “Our lead candidate, AUP-16, is currently in Phase 2 clinical trials for diabetic foot ulcers. We are actively seeking strategic partners and investors for our €35 million Series B round to accelerate our development.”
Swiss Biotech Day has become a premier global conference for life sciences, attracting over 2,500 participants from more than 40 countries in 2024. This year’s theme, The Power of Global Collaboration, emphasizes the importance of cross-border partnerships and innovation in the biotech industry.
About AUP-16
AUP-16 is a genetically engineered Lactococcus Cremoris, a non-pathogenic, probiotic bacteria, expressing human basic fibroblast growth factor (FGF-2, bFGF), interleukin-4 (IL-4) and macrophage colony stimulating factor (CSF-1, mCSF) – all in one product and accepted as one active pharmaceutical ingredient from regulatory perspective. AUP-16 is topically applied on chronic wounds and covered by wound dressing (e.g. in diabetic foot ulcers, venous leg ulcers or other ulcer types). In the wound AUP-16 acts as millions of bioreactors producing the therapeutic proteins, which are designed to i) halt chronic inflammation in the wound, ii) induce growth of new blood vessels, and iii) promote granulation tissue formation and skin re-epithelization – all in one product.
About Aurealis Therapeutics
Aurealis Therapeutics AG is a Swiss-Finnish clinical-stage company developing scalable and low COGS multi-target cell and gene therapies allowing to modulate tissue microenvironment and tackle complex multi-factorial diseases such as chronic wounds, cancers, and inflammation. Aurealis modular gene therapy platform consists of non-pathogenic lactic acid bacterium Lactococcus cremoris, genetically engineered to produce and release multiple human therapeutic proteins in the body: cytokines, chemokines, growth factors, antibody fragments. These living bacterium act as millions of nanoscale bioreactors at the site of the disease, allowing multi-targeting as one product, to treat multifactorial diseases. Aurealis pipeline includes Chronic Wounds (AUP-16, ongoing Phase 2), Oncology (AUP-55, pre-clinical stage), Inflammation (AUP-60, discovery stage).
For more information:
Laurent Décory, COO
Email: laurent@aurealistherapeutics.com